Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IMVT
IMMUNOVANT, INC.
NASDAQ
$41.20
▼ DOWN 5.98% (-2.62)

KEY STATISTICS

Market Cap$8.50 B
52w High$45.42
52w Low$14.58
Dividend Yield—
Frequency—
P/E-14.61
Volume1.08M
Shares Out.206.40M

COMPANY

LEADERSHIP

Eric Venker
CHIEF EXECUTIVE
Eric Venker

COMPENSATION 2026

Salary$39,614
Stock Awards$8,287,949
Incentive Plan Pay$0
All Other Comp.$737,642
Total$15,334,600

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 21, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
315

PRICE TARGET

Target High$40.00
Target Low$40.00
Target Median$40.00
Target Consensus$40.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$7.09M
NOV
9
MON

PRICE

$41.20 ▼ DOWN 5.98% (−$2.62)
$41.25$42.00$42.75$43.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM41.20

About Immunovant, Inc.

https://immunovant.com ↗

Immunovant, Inc., a New York-based clinical-stage biopharmaceutical subsidiary of Roivant Sciences, develops monoclonal antibodies like batoclimab for autoimmune diseases, currently in Phase II trials for myasthenia gravis, thyroid eye disease, an...

INDUSTRY

Biotechnology

A PRODUCT IMMUNOVANT, INC. IS KNOWN FOR

IMVT-1402
IMVT-1402

IMVT-1402 is a fully human monoclonal antibody targeting FcRn, developed as a subcutaneous treatment for autoimmune diseases, and is Immunovant’s lead candidate due to its promising safety profile and late-stage clinical trial progress.

COMPETITORS

COMPETITOR
ARGX COMPARE
JNJ COMPARE
PFE COMPARE
VRDN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
145
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
1.01% · 2.7M
VTI
0.00% · 2.6M
XSU.TO
0.11% · 2.2M
SCHA
0.07% · 367.2K
FESM
0.15% · 233.0K
LABU
0.69% · 99.6K
XRS2.DE
0.12% · 76.4K
TMSL
0.08% · 54.4K
RSSL
0.12% · 40.7K
PRFZ
0.06% · 36.6K
BBSC
0.14% · 24.6K
JHSC
0.14% · 22.7K
BKMC
0.08% · 12.7K
BBC
0.78% · 9.3K
BIB
0.30% · 7.3K
NIXT
0.65% · 6.8K
MNTL
0.90% · 5.9K
GSSC
0.02% · 5.6K
FTKI
0.87% · 5.3K
SGRW
0.73% · 4.9K
ETLZ.DE
0.09% · 4.7K
STXK
0.16% · 3.3K
ESSC
0.33% · 3.2K
RFLR
0.13% · 2.9K
TILT
0.00% · 2.4K
AVLC
0.01% · 2.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
40.98%
HOLDERS
305
TOP 12 OF 305 · RANKED BY POSITION SIZE
Fmr LLC
17.0M sh · $431.9M
Deep Track Capital, LP
11.5M sh · $293.02M
Vanguard Group Inc
7.8M sh · $197.75M
Blackrock, Inc.
7.2M sh · $276.68M
Armistice Capital, LLC
5.8M sh · $94.08M
Farallon Capital Management LLC
5.8M sh · $223.67M
Baker Bros. Advisors LP
5.5M sh · $135.57M
T. Rowe Price Investment Management, Inc.
5.2M sh · $83.25M
Blackrock Inc.
4.9M sh · $129.79M
Morgan Stanley
4.8M sh · $123.2M
State Street Corp
4.6M sh · $177.89M
Tcg Crossover Management, LLC
4.5M sh · $171.77M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
Pande Atul
Purchase · 1.5K shares
2026-08-28
★
DIRECTOR
Pande Atul
Sale · 1.5K shares
2026-08-28
★
OFFICER: CHIEF OPERATING OFFICER
Gloria Melanie
Sale · 3.1K shares
2026-08-20
★
DIRECTOR
Pande Atul
Purchase · 1.5K shares
2026-07-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 1
HOLD 1
NEUTRAL 1
OUTPERFORM 1
8 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Citigroup BUY Guggenheim BUY Truist Securities HOLD B of A Securities BUY HC Wainwright & Co. BUY Goldman Sachs NEUTRAL Wolfe Research OUTPERFORM

SECTORS PEERS

PEERPRICE
KYMR$118.15COMPARE
PRAX$344.75COMPARE
CRNX$84.84COMPARE
ACAD$29.11COMPARE
DYN$25.07COMPARE
VKTX$32.16COMPARE
NAMS$25.90COMPARE
RARE$25.61COMPARE